An observational study in Osteoarthritis, Rheumatoid Arthritis and Post-traumatic Arthritis, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Osteoarthritis by Zimmer Biomet — 4 open to participants now, 24 under way, none of them phase 3. Osteoarthritis · Zimmer Biomet.
Among the 101 studies in Osteoarthritis by Zimmer Biomet, this one is the 15th largest by planned enrollment of the 53 observational ones that give a count, is one of 8 that started in 2011, is one of 53 observational ones, reaches primary completion later than 3 of the 23 other live ones, and was the 41st registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →4 of the 101 studies in Osteoarthritis by Zimmer Biomet are open now, in 8 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States, Australia, Finland and 5 more countries
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2011.
This study's planned enrollment of 200 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Median enrollment 133 across the 48 interventional studies, 118 across the 53 observational. Of the 65 that completed or were terminated, 33 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
6 of the studies in Osteoarthritis by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT03404778Zimmer BiometComprehensive Reverse Shoulder Data Collection | 2026-12 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 101 studies in Osteoarthritis by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.
The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be collected and analyzed to monitor pain, function, and survivorship and to confirm the performance of the Trabecular Metal Reverse Shoulder System.
Performance will be evaluated by monitoring the frequency and incidence of adverse events as well as by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Trabecular metal Reverse Shoulder System.
Pain and functional performance will be measured using the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE), survivorship will be based on removal or intended removal of the device, health status will be determined by evaluation of the Short Form Survey12 (SF-12) as well as Adverse Events (AEs) and radiographic parameters analysis of x-rays.
Each investigator will screen from his/her patients who suffer from osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreduciable 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff dificiency or failed total shoulder arthroplasty (both glenoid and humeral components require revision) who meet the inclusion/exclusion criteria stated in the protocol
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
Device: Trabecular Metal Reverse Shoulder System
Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
Also known as: TM Reverse Shoulder System, TM Reverse System, TM Reverse
Survivorship
Based on removal or intended removal of the device and determined using the Kaplan-Meier method.
Time frame: 10 Years
Pain and Functional Performance
Measurements will be based on the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE)
Time frame: 10 Years
Started Jan 2011 (actual). Primary completion is estimated for Dec 2026, 191 months after the start.
Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 191 months is above that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.